Saatja: "RLT Academy" <
[email protected]>
Teema: SAVE THE DATE | Policy Recommendations Launch Event | Irish College Leuven’s Auditorium/Online | 16 July 2024 | 14:00 - 16:00
Kuupäev: 2024-06-20 07:57
On behalf of the Radioligand Therapy (RLT) Academy Consortium (Erasmus+
Project), we are thrilled to announce the upcoming launch of the RLT Academy
Policy Recommendations. This significant event which will serve as the
closing of the RLT first edition is scheduled for 16 July 2024, from 14:00
to 16:00, at the Irish College Leuven’s Auditorium and online, followed by a
cocktail reception.
The RLT Academy is launching a comprehensive set of policy recommendations,
developed by established experts in the nuclear medicine field, to advance
the adoption of RLT by addressing critical barriers to its implementation.
You can find the Save the Date attached to this email; the agenda will be
sent shortly. Following the event, a networking reception will be held.
This is a unique opportunity to network, share ideas, and be part of a
community that is shaping the future of cancer care through this
breakthrough treatment across Europe. We would be delighted to see you
there!
To register for this event either in-person or online, please
<https://forms.office.com/Pages/ResponsePage.aspx?id=5LJAWkDRpUKiid1kkOMNHWX3lxzdkhBDiPMrt6gEysNUMVk5SUtCUlpKWks5RFpPRUVJQ0tKUkpSQy4u>
CLICK HERE.
Kind regards,
Marietta on behalf of the RLT Academy Secretariat
POLICY RECOMMENDATIONS
Launch Event
16 July 2024
Irish College Leuven’s Grand Auditorium/Online
14:00 - 16:00, followed by a cocktail reception
Join us for a groundbreaking event as we mark the end of the first edition of
the RLT Academy Project – by launching a set of policy recommendations to
present to policymakers the current challenges and potential solutions for
improving RLTs uptake by healthcare professionals and healthcare national
systems.
Radioligand therapy (RLT) is an innovative type of nuclear
medicine that targets markers on tumor cells or their microenvironment, with the goal of
delivering the treatment mostly to the affected tumor cells, while limiting unwanted
effects on healthy cells.
Bringing together established experts in the medical fields relevant to RLT, the RLT
Academy is launching a set of policy recommendations to advise policymakers on
overcoming barriers to RLT adoption.
Ensuring proper patient access to RLT in Europe requires addressing barriers such as
healthcare infrastructure, regulatory contexts, and stakeholder cooperation from regional
to European levels. These policy recommendations will build on best practices from the
project and outline concrete actions for policymakers to take.
Please join us for this unique gathering to promote cutting-edge expertise in nuclear
medicine and advanced Radioligand Therapy (RLT) for cancer care.
Register here
Consortium Leader Full Partners Associate Partners
Project Management